anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Retroperitoneal fibrosis is a rare disease characterized by chronic inflammation and fibrosis in the retroperitoneal space that may wrap around the ureter and cause an obstruction. Here we present the cases of three patients diagnosed and treated between April and August 2022.
CASE PRESENTATION: Here we present three cases of retroperitoneal fibrosis. Imaging revealed hydronephrosis and/or ureteral dilation, whereas laboratory findings such as erythrocyte sedimentation rate, C-reactive protein, and immunoglobulin G4 were abnormal. Serum creatinine and blood urea nitrogen levels suggested renal injury. Additionally, two patients had unclear diagnoses from other hospitals. Later, all patients underwent ureteral stenting and laparoscopic ureterolysis at our hospital and simultaneous diagnosis by biopsy. The two patients with high immunoglobulin G4 levels exhibited extremely severe fibrosis. After discharge, each received maintenance prednisone to prevent recurrence as well as methotrexate, followed by follow-up every 3 months. Fortunately, serum creatinine, blood urea nitrogen, and intravenous urography findings remained normal with an average follow-up of 8.5 months.
CONCLUSION: Here we discovered interesting findings in the diagnosis and treatment of retroperitoneal fibrosis, including the stable effect of medical plus surgical treatment, an unclear ureteral obstruction etiology, and the relationship between immunoglobulin G4 level and fibrosis hardness. However, the mechanisms behind these new findings require further study.
A crude propolis extract or concentrated extract of propolis are extracted using solvents, leading to the sepn. of all components according to their bioactivity and enhancing the efficiency of each fraction. - Propolis or an extract of propolis is mixed with 0.1-11 pts. wt. carbohydrate based adsorbent or active charcoal and 0.1-15 pt. wt. water. Solvents are to be removed if the starting material was propolis extract. The resulting pulp is solvent extracted with single solvents or suitable mixtures in one or consecutive steps, the solvent types being: aliphatic, cycloaliphatic or aromatic hydrocarbons, ethers, chlorinated hydrocarbons, ketones, esters or alcohols, at temps. of 4 deg.C and solvent b.pt. Water or water solvent mixts. at 10-80 deg.C can beused respectively. The sequence used in extraction is optional and the final fractions can be freed from solvents if required.
Acute liver failure secondary to metastatic melanoma is exceedingly rare with the literature limited to case reports. The disease itself presents with vague symptoms making diagnosis difficult without a high clinical suspicion. Further to this, the prognosis of acute liver failure secondary to metastatic melanoma is dismal. We present the case of a 59-year-old male with a distant history of previously excised cutaneous melanoma who presented to our institution with abdominal pain and liver enzyme derangement suggestive of acute hepatitis. Due to progressive derangement in liver function and cross-sectional imaging suggestive of an infiltrative cause, a left axillary lymph node was biopsied which demonstrated metastatic melanoma. The patient subsequently deteriorated into acute liver failure and despite acute treatment of his underlying metastatic melanoma died 17 days post initial presentation. This case highlights an uncommon cause of acute liver failure as well as the poor prognosis associated with acute liver failure secondary to metastatic melanoma.
The present invention concerne drugs and diagnostic agents as well as diagnostic, therapeutic and preventive methods for treating auto-immune and viral diseases in humans, these diseases being caused by pathogenic bacteria which are, in particular, micro-organisms colonizing human mucus membranes and secreting given exoproteins which display structural similarities to human proteins. Proteins similar to IgA protease which are absorbed particularly well by cells and present as antigens on MHC molecules are of particular significance in this respect. The IgA protease polyprotein (IPP) of pathogenic Neisseriae has a particularly marked homology to human proteins. For example, a given IPP peptide has marked homology to the articular proteins link and aggrekan. It is thus proven, for example, that the IPP is an etiological agent of rheumatoid arthritis (RA). The auto-immune reaction is further encouraged by other properties of the IPP-producing Neisseriae and IPPs. A particularly important property is the ability of the IPP to activate viruses and viral elements. This concerns in particular the activation of proviral retroviruses and endogenic retroviruses in humans. Further auto-immune reactions are induced in humans owing to the activation of viruses and viral elements. The development of acquired immune deficiency syndrome (AIDS) is also explained by the IPP-dependent activation of the HIV provirus. The properties according to the invention of the pathogenic Neisseriae and the IPPs formed thereby give rise to numerous novel diagnostic, therapeutic and preventive processes.
The purpose is to study the safety and effectiveness of a new drug called "anti-TAC" (anti-CD25) Monoclonal Antibody used together with low dose Cyclosporine in the treatment of psoriasis. While the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes, which become activated in the skin. It is believed that these activated cells are responsible for the changes you see as the rash of psoriasis. Anti-TAC (anti-CD25) Monoclonal Antibody is designed to block the activation of these lymphocytes. Because the anti-TAC (anti-CD25) Monoclonal Antibody targets the specific cells involved in the symptoms of psoriasis, this new drug may be a better way to treat psoriasis. The second drug, Cyclosporine, is an FDA-approved drug in the treatment of psoriasis. There is evidence in the laboratory that Cyclosporine and anti-TAC, used together, will have an additive effect. An additional benefit of this study is that we are using a lower dose of cyclosporine than is usually given when it is used alone because it is being used together with anti-TAC. This should reduce the side effects usually seen with higher doses of Cyclosporine when it is used as a single drug for psoriasis. The purpose of this study is to test the safety and effectiveness of anti-TAC (Monoclonal Antibody and low dose cyclosporine in patients with active, moderate to severe psoriasis vulgaris. We also hope to gain more information on how anti-TAC works in the body
The invention discloses a Pu'er tea extract, a composition thereof, a preparation method and a product containing the same. The Pu'er tea extract is prepared by the following steps: adding the Pu'er tea into water of which the weight is 6-15 times of the weight of the Pu'er tea for performing water distillation; collecting section by section for 0.2-10 h; and merging the distillates with the maximum absorption wavelength of 260-290 nm to obtain the Pu'er tea extract. The invention also discloses a composition containing the extract. The composition is formed by mixing an inclusion compound of the extract and an acidity regulator according to the weight part ratio of (80-140):(0.3-20). The composition is prepared by the following steps: preparing the aqueous solution of the inclusion compound; freeze-drying or spray-drying to obtain the inclusion compound; and fully and uniformly mixing the inclusion compound and the acidity regulator to obtain the composition. The composition provided by the invention has the specific aroma and mouthfeel of the Pu'er tea and can be prepared into tea beverages, health care products, medicines and the like; and moreover, the composition has the advantages of good solubility, stable quality, simple preparation process, and low cost.
In the clinical studies with specific instructions to take HYSINGLA ER with adequate water to swallow the tablet, 11 out of 2476 subjects reported difficulty swallowing HYSINGLA ER. These reports included esophageal obstruction, dysphagia, and choking, one of which had required medical intervention to remove the tablet [see Adverse Reactions (6)].

Instruct patients not to pre-soak, lick, or otherwise wet HYSINGLA ER tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in the mouth.

Patients with underlying gastrointestinal disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at greater risk of developing these complications. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying gastrointestinal disorders resulting in a small gastrointestinal lumen.

Pediatric patients may be at increased risk of esophageal obstruction, dysphagia, and choking because of a smaller gastrointestinal lumen if they ingest HYSINGLA ER [see Use in Specific Populations (8.4)].
The aim of this study was to explore the functions and molecular mechanisms of the WNK lysine deficient protein kinase 1 (WNK1) in the development of ovarian cancer. Firstly, loss- and gain-of-function assays were carried out and subsequently cell proliferation, apoptosis, invasion and migration were detected. Furthermore, WNK1 action on glucose uptake, lactate production and adenosine triphosphate (ATP) level were assessed. The roles of WNK1 on cisplatin resistance were explored using CCK-8, colony formation, and flow cytometry in vitro. Immunohistochemistry, Western blot and qRT-PCR were conducted to determine the protein and mRNA expression. Additionally, tumor growth in vivo was also monitored. We found that the overexpression of WNK1 predicted a bad prognosis of ovarian cancer patients. WNK1 enhanced the malignant behavior and facilitated glycolysis of ovarian cancer cells. Moreover, WNK1 increased cisplatin resistance in ovarian cancer cells. Mechanistically, we found that WNK1 expression was promoted by CREB1 at the transcriptional level. And CREB1 could facilitate ovarian cancer cells malignant behavior through target upregulating WNK1. Besides, we also showed that WNK1 facilitated the malignant behavior by accelerating HIF-1 expression. In xenograft tumor tissues, the downregulation of WNK1 significantly reduced HIF-1α expression. These data demonstrated that the CREB1/WNK1 axis could promote the tumorigenesis of ovarian cancer via accelerating HIF-1 expression, suggesting that the CREB1/WNK1 axis could be a potential target during the therapy of ovarian cancer.
High doses of tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 mcg tiotropium in 6 healthy volunteers. In a study of 12 healthy volunteers, bilateral conjunctivitis and dry mouth were seen following repeated once-daily inhalation of 141 mcg of tiotropium.

Accidental Ingestion   
Acute intoxication by inadvertent oral ingestion of SPIRIVA capsules is unlikely since it is not well-absorbed systemically.

A case of overdose has been reported from postmarketing experience. A female patient was reported to have inhaled 30 capsules over a 2.5 day period, and developed altered mental status, tremors, abdominal pain, and severe constipation. The patient was hospitalized, SPIRIVA HandiHaler was discontinued, and the constipation was treated with an enema. The patient recovered and was discharged on the same day.

No mortality was observed at inhalation tiotropium doses up to 32.4 mg/kg in mice, 267.7 mg/kg in rats, and 0.6 mg/kg in dogs. These doses correspond to 7300, 120,000, and 850 times the recommended human daily inhalation dose on a mg/m2 basis, respectively. These dose multiples may be over-estimated due to difficulties in measuring deposited doses in animal inhalation studies.
The present invention discloses a new coronal virus. Most of the viruses are circular. The periphery of the virus is provided with fiber bulges arranged in a coronal shape. The diameter of the present invention is from 80 nm to 120 nm. The present invention is distributed in cytoplasm. The present invention is separated from the specimens of serious acute respiratory system syndrome patients, and can produce CPE after being inoculated to sensitive cells. The present invention can specifically react with the serum of non-typical pneumonia patients in clinical diagnosis, and is an SARS coronal virus.
Examples of the present technology may include methods for operating a blood analyzer. The method may include passing a control material through a hematology analyzer. The control material may include a first cell population and a second cell population. The method may further comprise determining a first cell population volume measurement and a second cell population volume measurement. A first value of the first cell population distribution width and a second value of the second cell population distribution width may be calculated. The method may include comparing the first value to a first reference range. The method may further include comparing the second value to a second reference range. Further, the method may include classifying an operational state of the blood analyzer based on a comparison of the first value to the first reference range and based on a comparison of the second value to the second reference range.
Preservative treatment of a tea obtd. by fermentation of water-oat leaves, which contains valuable nutrients such as proteins, carbohydrates, fats and mineral salts and also contains medicinal agents which can be used in digestive disorders, circulatory disorders, atherosclerosis, eye diseases, pyorrhoea and suppurations, as well as in the treatment of wounds, comprises (a) mixing the tea with animal secretions or fish blood contg. N, P, K, Ca and water, (b) illuminating and aerating the mixt. in order to develop heat-resistant microorganisms or thermophilic bacteria, (c) treating with water, (d) boiling in order to destroy saprophytic bacteria while retaining the activity of the heat-resistant microorganisms or thermophilic bacteria, (e) placing the boiled liquid mixture in the sun to cultivate the thermophilic bacteria, and (f) spraying the supernatant liquid onto tea obtd. by fermentation of water-oat leaves. The new preservative treatment affords protection against degradation by saprophytic bacteria without using antiseptics such as boric acid or salicylic acid.
Participants will receive 1 doses of MMR. Blood sampling will be performed on Day 0 and Day 30.
Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks. Follow-up tests is also included after 6-, 12- and 24 months.
Effective management of excessive bleeding requires liquid hemostatic agents, especially in scenarios involving uncompressible and postoperative hemorrhage. This study introduces the microbial exopolysaccharide floccuronic acid (FA) as a liquid hemostatic agent, characterized by a high weight average molecular weight of 2.38 × 108 Da. The investigation focuses on the flocculation effect, hemostatic efficiency in both in vitro and in vivo settings, elucidating its hemostatic mechanism, and assessing its safety profile. Results reveal that FA solution significantly accelerates the coagulation process, leading to the formation of compact clots while specifically interfering with fibrin. Notably, FA demonstrates excellent hemostatic effects in animal liver models and a rat arterial rebleeding model. The biocompatible and biodegradable characteristics further underscore FA's potential as a valuable liquid hemostatic material, particularly suited for non-compressible and re-bleeding scenarios.
Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Cellular uptake includes at least partial uptake into the cytosol. Boronation includes ligating, crosslinking or otherwise bonding one or more phenylboronic acids substituted to contain a reactive group to a cargo molecule. Boronation also includes ligating, crosslinking or otherwise bonding a phenylboronated oligopeptide to a cargo molecule. The phenylboronate groups are optionally conjugated to the cargo molecule via linking moieties that can be selectively cleaved, such cleavable linkers can allow the phenylboronate groups to be removed from the cargo molecule after the boronated cargo molecule is introduced into the cell. The invention includes certain phenylboronates which are boronation reagents, certain boronated oligopeptides and certain boronated peptides and proteins. The invention also includes kits for enhancing cellular uptake of cargo molecules by boronation with one or more phenylboronates or boronated oligopeptides.
For performing Point to Point Tactile Localization, the child will be seated and the examiner will locate a point on the forearm of the blinded child by a black marker pen. Then the child will be asked to relocate the point with the help of red marked in blindfolded state. The distance between black point and red point (in cm) will be noted as the acuity of tactile localization. 15 areas in upper limb will be selected and PPTL will be performed on them. The fifteen areas are, phalanges of the palmer area of the little finger (palm 1), phalanx of the middle finger of the Palmer area (palm 2), phalanx of the thumb area of palm (palm 3), first dorsal interosseous (palm 4), mid last part of the forearm (forearm 1), middle of the medial forearm (forearm 2), medial side of the forearm (forearm 3), the lower portion of the arm (arm 1), middle posterior of arm (arm 2), lateral side of upper arm (arm 3), lower portion of medial arm (arm 4), middle portion of arm (arm 5), the median upper arm (arm 6), lower side arm (arm 7), and upper side of arm (arm 8). Mean of three readings will be used for estimating the normative reference value of tactile localization by PPTL technique.
The invention provides enramycin dry suspension which contains 2 percent to 8 percent of enramycin, 20 percent to 60 percent of filler, 10 percent to 40 percent of flavoring, 5 percent to 30 percent of suspending aid and 1 percent to 10 percent of wetting agent. In addition, the invention provides a preparation method of the enramycin dry suspension. Compared with premix, when being used temporarily, the enramycin dry suspension can be dispersed into supensoid agent for oral taking only by being added with water and shaken; when being used, the enramycin dry suspension can become solution only by being added with water, the dispersion is uniform, and the defects when the premix is used are overcome; meanwhile, the specific surface area of the enramycin dry suspension is larger than that of the premix, the absorption is quick, the bioavailability is high and the cure rate is higher. Compared with the solution, the enramycin dry suspension is always in a dry state without water, so that the stability is more easily realized. In addition, the enramycin dry suspension is conveniently used, so that a lot of manpower and materials are saved. But a technology of preparing dry suspension with the enramycin is not yet reported.
Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Carriers of CYP2C19 loss-of-function alleles have increased adverse events after percutaneous coronary intervention, but limited data are available for older patients. We aimed to evaluate the prognostic impact of CYP2C19 genotypes on clinical outcomes in older patients after percutaneous coronary intervention.
METHODS AND RESULTS: The study included 1201 older patients (aged ≥75 years) who underwent percutaneous coronary intervention and received clopidogrel-based dual antiplatelet therapy in South Korea. Patients were grouped on the basis of CYP2C19 genotypes. The primary outcome was 3-year major adverse cardiac events, defined as a composite of cardiac death, myocardial infarction, and stent thrombosis. Older patients were grouped into 3 groups: normal metabolizer (36.6%), intermediate metabolizer (48.1%), and poor metabolizer (15.2%). The occurrence of the primary outcome was significantly different among the groups (3.1, 7.0, and 6.2% in the normal metabolizer, intermediate metabolizer, and poor metabolizer groups, respectively; P=0.02). The incidence rate of all-cause death at 3 years was greater in the intermediate metabolizer and poor metabolizer groups (8.1% and 9.2%, respectively) compared with that in the normal metabolizer group (3.5%, P=0.03) without significant differences in major bleeding. In the multivariable analysis, the intermediate metabolizer and poor metabolizer groups were independent predictors of 3-year clinical outcomes.
CONCLUSIONS: In older patients, the presence of any CYP2C19 loss-of-function allele was found to be predictive of a higher incidence of major adverse cardiac events within 3 years following percutaneous coronary intervention. This finding suggests a need for further investigation into an optimal antiplatelet strategy for older patients.
REGISTRATION: URL: https://clinicaltrials.gov. Identifier: NCT04734028.
The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
Elevated body mass index (BMI) has been linked to severe influenza illness and impaired vaccine immunogenicity, but the relationship between BMI and clinical vaccine effectiveness (VE) is less well described. This secondary analysis of data from a test-negative study of outpatients with acute respiratory illness assessed BMI and VE against medically attended, PCR-confirmed influenza over seven seasons (2011-12 through 2017-18). Vaccination status was determined from electronic medical records (EMR) and self-report; BMI was estimated from EMR-documented height and weight categorized for adults as obesity (≥ 30 kg/m2), overweight (25-29 kg/m2), or normal and for children based on standardized z-scales. Current season VE by virus type/subtype was estimated separately for adults and children. Pooled VE for all seasons was calculated as 1-adjusted odds ratios from logistic regression with an interaction term for BMI and vaccination. Among 28,089 adults and 12,380 children, BMI category was not significantly associated with VE against outpatient influenza for any type/subtype. Adjusted VE against A/H3N2, A/H1N1pdm09, and B in adults ranged from 16-31, 46-54, and 44-57%, and in children from 29-34, 57-65, and 50-55%, respectively, across the BMI categories. Elevated BMI was not associated with reduced VE against laboratory confirmed, outpatient influenza illness.